Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms.
- Published in:
- Current Hematologic Malignancy Reports, 2022, v. 17, n. 5, p. 113, doi. 10.1007/s11899-022-00667-3
- By:
- Publication type:
- Article
Works matching IS 15588211 AND DT 2022 AND VI 17 AND IP 5
Results: 6
1
2
ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms.
- Published in:
- Current Hematologic Malignancy Reports, 2022, v. 17, n. 5, p. 105, doi. 10.1007/s11899-022-00666-4
- By:
- Publication type:
- Article
3
Management of Chronic Myeloid Leukemia in Children and Young Adults.
- Published in:
- Current Hematologic Malignancy Reports, 2022, v. 17, n. 5, p. 121, doi. 10.1007/s11899-022-00673-5
- By:
- Publication type:
- Article
4
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.
- Published in:
- Current Hematologic Malignancy Reports, 2022, v. 17, n. 5, p. 127, doi. 10.1007/s11899-022-00672-6
- By:
- Publication type:
- Article
5
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.
- Published in:
- Current Hematologic Malignancy Reports, 2022, v. 17, n. 5, p. 140, doi. 10.1007/s11899-022-00671-7
- By:
- Publication type:
- Article
6
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.
- Published in:
- Current Hematologic Malignancy Reports, 2022, v. 17, n. 5, p. 155, doi. 10.1007/s11899-022-00670-8
- By:
- Publication type:
- Article